URGN Stock Summary and Trading Ideas (Urogen Pharma Ltd. - | NASDAQ:URGN)

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Urogen Pharma Ltd. - trades on the NASDAQ stock market under the symbol URGN.

As of March 14, 2025, URGN stock price climbed to $11.07 with 258,521 million shares trading.

URGN has a market cap of $510.26 million. This is considered a Small Cap stock.

Last quarter Urogen Pharma Ltd. - reported $25 million in Revenue and -$.80 earnings per share. This fell short of revenue expectation by $-685,000 and missed earnings estimates by -$.08.

In the last 3 years, URGN traded as high as $24.13 and as low as $4.85.

The top ETF exchange traded funds that URGN belongs to (by Net Assets): IWM, IWO, IBB, IZRL, VTWO.

URGN has underperformed the market in the last year with a return of -22.7%, while SPY returned +11.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in URGN shares. However, URGN has outperformed the market in the last 3 month and 2 week periods, returning -2.5% and +17.0%, while SPY returned -6.5% and -5.3%, respectively. This indicates URGN has been having a stronger performance recently.

URGN support price is $10.41 and resistance is $11.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that URGN shares will trade within this expected range on the day.